Mechanism and clinical management of Bruton's tyrosine kinase inhibitor-mediated bleeding
10.12354/j.issn.1000-8179.2024.20240468
- VernacularTitle:布鲁顿酪氨酸激酶抑制剂介导的出血机制及临床管理
- Author:
Song LIXIA
1
;
Kang HONGYANG
;
Han GUOJIANG
;
Liu JIE
;
Fan LING
;
Tong CHANGQING
Author Information
1. 河北北方学院(河北省张家口市 075000)
- Keywords:
BTK inhibitor;
hemorrhage;
adverse event;
clinical management
- From:
Chinese Journal of Clinical Oncology
2024;51(14):737-741
- CountryChina
- Language:Chinese
-
Abstract:
Bruton's tyrosine kinase(BTK)inhibitors are novel drugs targeted for the treatment of B-cell lymphoma.BTK inhibitors have pro-duced strong curative effects,especially for mantle cell lymphoma(MCL),chronic lymphocytic leukemia/small lymphocytic lymphoma(CLL/SSL),and Waldenstr?m's macroglobulinemia(WM).However,the adverse effect of bleeding has gradually been noted with the wide-spread use of BTK inhibitors in clinical practice.Bleeding events are caused by the off-target effects of BTK inhibitors,which affect platelet function through multiple signaling pathways during use.Bleeding affects patient treatment and threatens their quality of life.As such,the clinical management of bleeding should be strengthened.This paper provides a review of the mechanisms of action and clinical manage-ment of bleeding caused by BTK inhibitors.
